Stocktoria
Anbio Biotechnology NNNN
Anbio Biotechnology (NNNN) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $8.6M at a 74.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | 1/9 | -4.17 | — | — |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
FAQ
Is NNNN financially healthy?
Anbio Biotechnology's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does NNNN pay a dividend?
No, Anbio Biotechnology does not currently pay a dividend.
How profitable is NNNN?
In FY2025, Anbio Biotechnology had a net margin of 74.1% and a return on equity of 21.2%.
What is NNNN's P/E ratio?
Anbio Biotechnology's trailing price-to-earnings (P/E) ratio is about 326.5×, based on its latest annual earnings.
Is NNNN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Anbio Biotechnology: a Piotroski F-score of 4/9, a P/E of about 326.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.